VRTX Vertex Pharmaceuticals Incorporated

170.06
-3.36  -2%
Previous Close 173.42
Open 171.38
Price To Book 14.96
Market Cap 43460199432
Shares 255,558,035
Volume 913,948
Short Ratio
Av. Daily Volume 1,472,991

NewsSee all news

  1. 5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019
  2. Health Canada Grants Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) for Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease
  3. Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
  4. Should Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Be Your Next Stock Pick?
  5. 5 Top Drug/Biotech Merger & Acquisition Targets for 2019

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181139004
  2. 8-K - Current report 181136520
  3. S-8 - Securities to be offered to employees in employee benefit plans 18972132
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 18971827
  5. 8-K - Current report 18968815

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 positive data released November 27, 2018. 14% improvement in ppFEV1 cf placebo.
VX-659 in combination with tezacaftor and ivacaftor
Cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation (F508del/Min)
PDUFA date under priority review February 28, 2017. Approval announced February 12, 2018.
Tezacaftor (VX-661) / ivacaftor
Cystic fibrosis - Two Copies of the F508del Mutation
Phase 2 data released July 18, 2017. ppFEV1 of 12.0 percentage points.
VX-440 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Approved December 29, 2014.
KALYDECO
Cystic fibrosis (CF) ages 6 and older who have the R117H mutation
Phase 2 primary endpoint met - January 25, 2017.
VX-150
Osteoarthritis
CRL issued February 5, 2016.
KALYDECO (ivacaftor)
Cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations.
Approved July 2, 2015.
Lumacaftor and ivacaftor
Cystic fibrosis (CF) ages 12 and older who have two copies of the F508del mutation
Approved March 17, 2015.
KALYDECO (ivacaftor)
Children ages 2 to 5 with cystic fibrosis who have the G551D or one of the eight additional gating mutations
NDA filing due 1Q 2018.
ORKAMBI
Two Copies of the F508del Mutation - children ages 2 to 5
Phase 3 data released October 25, 2017 - primary endpoint not met.
Tezacaftor (VX-661) / ivacaftor
Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in a gating mutation
Phase 3 trial terminated August 2016
VX-661
Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in minimal CFTR Function
Approved September 28, 2016.
ORKAMBI
Cystic fibrosis (CF) ages 6-11 who have F508del mutation
Phase 2 data released July 18, 2017. ppFEV1 of 9.7 percentage points.
VX-152 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Phase 2 data due early 2019.
VX-150
Neuropathic pain
Phase 2 data due released February 14, 2018. Primary endpoint met.
VX-150
Acute pain following bunionectomy surgery
Phase 3 data due 1Q 2019.
VX-445 in combination with tezacaftor and ivacaftor
Cystic fibrosis (CF) who have two copies of the F508del mutation
Phase 3 positive data released November 27, 2018. 10% improvement in ppFEV1 cf placebo.
VX-659 in combination with tezacaftor and ivacaftor
Cystic Fibrosis Who Have Two Copies of the F508del Mutation
Phase 3 data due 1Q 2019.
VX-445 in combination with tezacaftor and ivacaftor
Cystic fibrosis (CF) who have one copy of the F508del mutation and one minimal function mutation
Phase 1/2 trial initiated 4Q 2018.
CTX001
Sickle cell disease
Phase 1/2 trial enrolling.
CTX001
Beta-thalassemia
FDA Approval announced August 7, 2018.
Ivacaftor
Cystic fibrosis (CF) ages 2 to 5.
Approval announced August 15, 2018.
Lumacaftor and ivacaftor
Cystic fibrosis (CF) ages 1-2.
sNDA filing due late 2018.
Ivacaftor
Cystic Fibrosis (6-12 mths)
sNDA filing due late 2018.
Tezacaftor and ivacaftor
Cystic Fibrosis (Age 6-11)
Phase 2 monotherapy trial to commence 2H 2019.
VX-561
Cystic fibrosis who have a gating mutation

Latest News

  1. 5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019
  2. Health Canada Grants Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) for Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease
  3. Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
  4. Should Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Be Your Next Stock Pick?
  5. 5 Top Drug/Biotech Merger & Acquisition Targets for 2019
  6. Should You Avoid Vertex Pharmaceuticals Incorporated (VRTX)?
  7. 3 Highest-Growth Stocks in Today's Market
  8. Biotech Stock Roundup: ASH Meet in Focus, Gilead's Drugs Get Approval in China
  9. Monday Madness: Ready to Add Some Stocks to Your Holiday Wishlist?
  10. Top Analysts: Five 'Strong Buy' Stocks for 2019
  11. Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals
  12. Why Crispr Therapeutics Stock Is Up By 65% So Far in 2018
  13. How BioMarin Pharmaceutical’s Financials Look in November
  14. Moderna IPO On Path To Be Largest Offering Of Venture-Backed Biotech
  15. Wall Street Analysts Are Mostly Positive on BioMarin
  16. Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) to Treat Patients with Cystic Fibrosis Aged 12 to <24 months with Certain Mutations in the CFTR Gene
  17. Vertex Looks to Capture the Rest of Its Multibillion-Dollar Market
  18. Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed
  19. Biotech Stock Roundup: Pipeline Updates From CELG & VRTX, ZFGN Plunges on Hold News
  20. Today's Research Reports on Trending Tickers: Vertex Pharmaceuticals and Tesaro

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181139004
  2. 8-K - Current report 181136520
  3. S-8 - Securities to be offered to employees in employee benefit plans 18972132
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 18971827
  5. 8-K - Current report 18968815
  6. 8-K - Current report 18846672
  7. PX14A6G - Notice of exempt solicitation submitted by non-management 18811779
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 18784578
  9. 8-K - Current report 18778632
  10. DEF 14A - Other definitive proxy statements 18759007